Lactate dehydrogenase A regulates autophagy and tamoxifen resistance in breast cancer
Publication date: Available online 13 March 2019Source: Biochimica et Biophysica Acta (BBA) - Molecular Cell ResearchAuthor(s): Chandan Kanta Das, Aditya Parekh, Pratap Kumar Parida, Sujit Kumar Bhutia, Mahitosh MandalAbstractEstrogen receptor (ER) antagonist, tamoxifen has been universally used for the treatment of the ER-positive breast cancer; however, inevitable emergence of resistance to tamoxifen obstructs the successful treatment of this cancer. So, there is an immediate requirement for the search of a novel therapeutic target for treatment of this cancer. Acquired tamoxifen resistant breast cancer cell lines MCF-7 (MCF-7/TAM-R) and T47D (T47D/TAM-R) showed higher apoptotic resistance accompanied by induction of pro-survival autophagy compared to their parental cells. Besides, tamoxifen resistance was associated with reduced production of ATP and with overexpression of glycolytic pathways, leading to induced autophagy to meet the energy demand. Further, our study revealed that LDHA; one of the key molecules of glycolysis in association with Beclin-1 induced pro-survival autophagy in tamoxifen resistant breast cancer. Mechanistically, pharmacological and genetic inhibition of LDHA reduced the pro-survival autophagy, with the restoration of apoptosis and reverting back the EMT like phenomena noticed in tamoxifen resistant breast cancer. In total, targeting LDHA opened a novel strategy to interrupt autophagy and tamoxifen resistance in breast cancer.
Women know too little about alcohol's role in increasing breast cancer risk, a study suggests.
In conclusion, synthetic compound, (±)-kusunokinin and (±)-bursehernin, showed anticancer effects via the reduction of cell proliferation proteins and induction of apoptosis.
Researchers from the University of Southampton surveyed more than 200 patients and staff at a breast care centre in England and found knowledge about the link to alcohol was poor.
The Tomosynthesis Mammographic Imaging Screening Trial (TMIST) is a randomized breast screening trial that will help researchers learn about the best ways to find breast cancer in women who have no symptoms. It compares two Food and Drug Administration-approved types of digital mammography: standard digital mammography (2-D) with a newer technology called tomosynthesis mammography (3-D). Researchers are doing this trial because they do not know if 3-D mammography is better than 2-D mammography for breast cancer screening.For more information go tohttps://orwh.od.nih.gov/Air date: 6/20/2019 1:00:00 PM
Tiah Tomlin was diagnosed with an aggressive form of breast cancer at just 38. During her battle, she saw health disparities and a gap in support for black women - so she started nonprofits to fill them.
Publication date: Available online 17 June 2019Source: MethodsAuthor(s): Yuexu Jiang, Duolin Wang, Dong Xu, Trupti JoshiAbstractNowadays, large amounts of omics data have been generated and contributed to increasing knowledge about associated biological mechanisms. A new challenge coming along is how to identify the active pathways and extract useful insights from these data with huge background information and noise. Although biologically meaningful modules can often be detected by many existing informatics tools, it is still hard to interpret or make use of the results towards in silico hypothesis generation and testing....
New J. Chem., 2019, Accepted Manuscript DOI: 10.1039/C9NJ01834D, PaperMin Zheng, Yong-Jin Cao, Wei-Hua Cai, Xi Shi, Mou-Feng Wang, Yu-Jie Deng A potentiometric immunoassay based on copper(II) ion-selective electrode (Cu-ISE) was designed for the quantitative determination of carbohydrate antigen 15-3 (CA 15-3; a tumor marker associated with breast cancer). To construct... The content of this RSS Feed (c) The Royal Society of Chemistry
[Cameroon Tribune] A campaign for free testing scheduled from the 10-13 at Mbingo Baptist Hospital Bonaberi.
Abstract Breast cancer, one of the leading causes of death in women in the United States, challenges therapeutic success in patients due to tumor heterogeneity, treatment resistance, metastasis and disease recurrence. Knowledge of immune system involvement in normal breast development and breast cancer has led to extensive research into the immune landscape of breast cancer and multiple immunotherapy clinical trials in breast cancer patients. However, poor immunogenicity and T-cell infiltration along with heightened immunosuppression in the tumor microenvironment have been identified as potential challenges to the...
Condition: Breast Cancer Intervention: Diagnostic Test: Mammography outside official screening Sponsors: Tartu University Hospital; University of Tartu; North Estonia Medical Centre Recruiting